Jump to content

Deudextromethorphan/quinidine

From Wikipedia, the free encyclopedia
Deudextromethorphan/quinidine
Combination of
DeudextromethorphanSigma-1 receptor agonist, NMDA receptor antagonist, serotonin–norepinephrine reuptake inhibitor
QuinidineAntiarrhythmic agent, CYP2D6 inhibitor
Clinical data
Other namesAVP-786; CTP-786; d-DM/Q; d6-DM/Q; d-DXM/Q; d6-DXM/Q
Routes of
administration
By mouth

Deudextromethorphan/quinidine (d-DXM/Q; developmental code names AVP-786, CTP-786) is a combination of deudextromethorphan (d-DXM; deuterated (d6) dextromethorphan (DXM)) and quinidine (Q) which is under development by Avanir Pharmaceuticals for the treatment of a variety of neurological and psychiatric indications.[1][2] The pharmacological profile of d-DXM/Q is similar to that of dextromethorphan/quinidine (DXM/Q).[2] DXM and d-DXM act as σ1 receptor agonists, NMDA receptor antagonists, and serotonin–norepinephrine reuptake inhibitors, among other actions, while quinidine is an antiarrhythmic agent acting as a CYP2D6 inhibitor.[2] Quinidine inhibits the metabolism of DXM and d-DXM into dextrorphan (DXO), which has a different pharmacological profile from DXM.[2] Deuteration of DXM hinders its metabolism by CYP2D6 into DXO, thereby allowing for lower doses of quinidine in the combination.[2] This in turn allows for lower potential for drug interactions and cardiac adverse effects caused by quinidine.[2] As of September 2020, d-DXM/Q is in phase 3 clinical trials for agitation, phase 2/3 trials for schizophrenia, and phase 2 trials for brain injuries, impulse control disorders, major depressive disorder, and neurodegenerative disorders.[1]

References

[edit]
  1. ^ a b "Deudextromethorphan - Avanir Pharmaceuticals - AdisInsight".
  2. ^ a b c d e f Ahmed M, Malik M, Teselink J, Lanctôt KL, Herrmann N (July 2019). "Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia". Drugs Aging. 36 (7): 589–605. doi:10.1007/s40266-019-00668-7. PMID 30957198. S2CID 102348513.